top of page

GPCR News 

Post: Blog2_Post

GPCR Therapeutics welcomes Dr. Ed Brennan as their new Vice President, Head of Clinical Development

June 2022

"We’re delighted to welcome Dr Ed Brennan as our new Vice President, Head of Clinical Development.

Dr Brennan has extensive experience across all phases of clinical development, and across multiple therapeutic areas, including Oncology, Infectious Diseases, Immunology and Critical Care. He has led teams that have filed more than 10 Investigational New Drug Applications (IND), as well as multiple New Drug (NDA) and Supplemental New Drug Applications (SNDA).

Previous companies worked at include OrthoBiotech (OBI), a division of Johnson & Johnson and GlaxoSmithKline Consumer Healthcare, L.P. In 2007 he formed IndiPharm which was a full-service Contract Research Organization whose operational headquarters were in Mumbai, India. In 2016 the company was sold to Velocity fund partners and has been rebranded as InClinica.

He received his undergraduate Bachelor of Science Degree in Pharmacy from The Philadelphia College of Pharmacy and Science. He went on to study medicine at the Royal College of Surgeons in Ireland before receiving his Medical Degree from Temple University – Lewis Katz School of Medicine.

#biotech #lifesciences #appointment #GPCR #Oncology" Read more at the source

#DrGPCR #GPCR #IndustryNews

2 views0 comments

Recent Posts

See All

August 2022 "THOUSAND OAKS, Calif. and SAN CARLOS, Calif., Aug. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., (NASDAQ: CCXI), a biopharmaceutical company focused on orally admin